Neoadjuvant SCRT Plus Camrelizumab Shows Promising 3-Year Survival in Locally Advanced Rectal Cancer
A phase 2 trial demonstrated that neoadjuvant short-course radiotherapy followed by camrelizumab and CAPOX chemotherapy achieved an 80.2% three-year disease-free survival rate in locally advanced rectal cancer patients.
Gene-Edited Pig Kidney Functions in Macaque for Over Six Months in Chinese Study
Chinese scientists achieved a breakthrough by maintaining a gene-edited pig kidney's function in a macaque for 184 days, marking progress in xenotransplantation.